ZFIN ID: ZDB-FISH-150901-14755
Fish name: s843Tg
Genotype: s843Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by s843Tg
Human Disease Conditions Citations
cancer cancer xenotransplantation Ahn et al., 2015
cancer xenotransplantation Yang et al., 2017
cancer xenotransplantation Deng et al., 2015
cancer xenotransplantation Chiavacci et al., 2015
cancer xenotransplantation, chemical treatment: dexamethasone Kanada et al., 2014
glioblastoma cancer xenotransplantation Zeng et al., 2017
bacterial infectious disease bacterial treatment by injection: Mycobacteroides abscessus Kam et al., 2022
bacterial treatment by injection: Mycobacterium marinum M Torraca et al., 2017
type 2 diabetes mellitus chemical treatment by environment: D-glucose Carnovali et al., 2016
GENE EXPRESSION
Gene expression in s843Tg
RNA expression
Expressed Gene Structure Conditions Figures
alcama standard conditions 12 figures with image from 5 publications
chemical treatment: semaxanib Fig. 4 with image from Sakaguchi et al., 2008
arcn1a standard conditions Fig. 9 from Chen et al., 2017
arcn1b standard conditions Fig. 9 from Chen et al., 2017
arhgef17 standard conditions Fig. 5 from Yang et al., 2018
asip2b control Fig. 5 with image from Shainer et al., 2019
atoh8 standard conditions Fig. 3 with image from Place et al., 2017
chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 3 with image from Place et al., 2017
avp standard conditions Fig. 2 with image from Choi et al., 2016
avpr1ab control Fig. 3 from Page et al., 2019
chemical treatment: semaxanib Fig. 3 from Page et al., 2019
badb standard conditions Fig. 9 from Chen et al., 2017
baxb standard conditions Fig. 9 from Chen et al., 2017
bcl2a standard conditions Fig. 9 from Chen et al., 2017
bglap chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
birc2 standard conditions Fig. 2,  Fig. S3 from Santoro et al., 2007
ccl38.1 control Fig. 3 from Page et al., 2019
chemical treatment: semaxanib Fig. 3 from Page et al., 2019
cdh5 standard conditions Fig. 2 with image from Chetty et al., 2020
Fig. 3 from Chen et al., 2017
Fig. 2 with image from Xu et al., 2017
Fig. S9 from Kleaveland et al., 2009
cldn15lb standard conditions Fig. 2 with image from Cheung et al., 2012
col22a1 standard conditions Fig. 2 with image from Ton et al., 2018
copa standard conditions Fig. 9 from Chen et al., 2017
copg2 standard conditions Fig. 9 from Chen et al., 2017
crestin standard conditions Fig. 2 with image from Leigh et al., 2013
crip2 standard conditions Fig. 1 from Kim et al., 2014
csf1a standard conditions Fig. 5 from Mahony et al., 2016
csf1b standard conditions Fig. 5 from Mahony et al., 2016
csf3a standard conditions Fig. 5 from Mahony et al., 2016
csf3b standard conditions Fig. 5 from Mahony et al., 2016
cxcl11.1 bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
cxcl12a bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
cxcl18b bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
cxxc5a control Fig. 5 from Kim et al., 2014
ddit3 standard conditions Fig. 9 from Chen et al., 2017
dre-mir-138 standard conditions Fig. 1 with image from Morton et al., 2008
epoa standard conditions Fig. 5 from Mahony et al., 2016
esama chemical treatment by environment: IWR-1-endo Fig. S4 from Hübner et al., 2018
fabp4a control Fig. S2 with image from Zhang et al., 2017
chemical treatment by environment: sirolimus Fig. S2 with image from Zhang et al., 2017
fgfr1a control Fig. 1 with image from De Smet et al., 2014
fgfr2 control Fig. 1 with image from De Smet et al., 2014
fgfr3 control Fig. 1 with image from De Smet et al., 2014
fgfr4 control Fig. 1 with image from De Smet et al., 2014
flt1 control Fig. 3 from Wang et al., 2016
fn1a standard conditions Fig. 1 with image,  Fig. 3 with image,  Fig. 5 with image,  Fig. 6 with image,  Fig. 8 with image from Chiu et al., 2012
gbf1 standard conditions Fig. 3 from Chen et al., 2017
gja5a standard conditions Fig. 5 with image from Denis et al., 2019
gja5b standard conditions Fig. 5 with image from Denis et al., 2019
gnrh3 standard conditions Fig. 2 with image from Choi et al., 2016
hcrt standard conditions Fig. 2 with image from Choi et al., 2016
hlx1 control Fig. 3 from Page et al., 2019
chemical treatment: semaxanib Fig. 3 from Page et al., 2019
hmgcra control Fig. 3 from Page et al., 2019
chemical treatment: semaxanib Fig. 3 from Page et al., 2019
id2a standard conditions Fig. 1 with image,  Fig. 2 with image from Khaliq et al., 2015
il1b bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
kdr standard conditions Fig. 2 with image from Chetty et al., 2020
kdrl standard conditions Fig. 2 with image from Chetty et al., 2020
Fig. 3 from Xie et al., 2019
Fig. 5 from Duong et al., 2014
Fig. S6 from Cermenati et al., 2008
Fig. 1 with image from Jin et al., 2005
chemical treatment: LY294002 Fig. 6 from Xie et al., 2019
microgravity Fig. 3,  Fig. 5 from Xie et al., 2019
kitlgb standard conditions Fig. 5 from Mahony et al., 2016
klf2a control Fig. 4 with image from Otten et al., 2018
Fig. S12 from Wang et al., 2013
chemical treatment by environment: indirubin-3'-monoxime Fig. 4 with image from Otten et al., 2018
lcp1 standard conditions Fig. 6 from Bukrinsky et al., 2009
lft2 control Fig. 3 from Page et al., 2019
chemical treatment: semaxanib Fig. 3 from Page et al., 2019
lmo2 standard conditions Fig. 3 with image from Weiss et al., 2012
mfng control Fig. 3 from Page et al., 2019
chemical treatment: semaxanib Fig. 3 from Page et al., 2019
mia control Fig. 3 from Page et al., 2019
chemical treatment: semaxanib Fig. 3 from Page et al., 2019
mib1 standard conditions Fig. S4 from Wang et al., 2016
mir-ntu1 standard conditions Fig. 1 from Shi et al., 2019
mir10a standard conditions Fig. S1 from Wang et al., 2016
mir144 standard conditions Fig. 1 from Shi et al., 2019
mmp9 bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
mmp17a standard conditions Fig. 2 with image from Leigh et al., 2013
mmp17b standard conditions Fig. 2 with image,  Fig. 4 with image from Leigh et al., 2013
mnx1 standard conditions Figure 1 with image from Gong et al., 2020
mpx standard conditions Fig. 6 from Bukrinsky et al., 2009
nrg1 standard conditions Fig. 1 with image from Samsa et al., 2016
oxt standard conditions Fig. 2 with image from Choi et al., 2016
podxl2 standard conditions Fig. 4 with image from Herwig et al., 2011
rasip1 standard conditions Fig. 6. with image,  Fig. 8. with image from Lee et al., 2021
reck standard conditions Fig. 4 with image from Leigh et al., 2013
robo1 control Fig. 3 with image from Fish et al., 2011
sema3d standard conditions Fig. 2 with image from Hamm et al., 2016
sox2 standard conditions Figure 1 with image from Gong et al., 2020
sox11b standard conditions Fig. 3 from Schmitt et al., 2013
tfec standard conditions Fig. 1 from Mahony et al., 2016
thpo standard conditions Fig. 5 from Mahony et al., 2016
tm4sf18 control Fig. 3 from Page et al., 2019
chemical treatment: semaxanib Fig. 3 from Page et al., 2019
tmem204 control Fig. 3 from Page et al., 2019
chemical treatment: semaxanib Fig. 3 from Page et al., 2019
tnfa bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
tnfrsf1b chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
tnfrsf11b chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
tnfrsf21 control Fig. S3 with image from Tam et al., 2012
tnfsf11 chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
vegfaa control Figure 6 with image,  Figure 7 with image from Ki et al., 2019
hypoxia Figure 7 with image from Ki et al., 2019
Fig. 4 with image from Torraca et al., 2017
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-tagln standard conditions Fig. 3 with image,  Fig. 5 with image,  Fig. 6 with image,  Fig. 7 with image,  Fig. S2 with image from Santoro et al., 2009
Ab1-lrp1 control Fig. 5 from Pi et al., 2012
Ab2-slc2a1 control Fig. S3 with image,  Fig. S5 with image from Tam et al., 2012
Ab2-tjp1 standard conditions Fig. S1 with image from Xie et al., 2010
Ab5-akt standard conditions Fig. 3 with image from Gong et al., 2019
Ab1-cldn5 chemical treatment: bradykinin Fig. 6 with image from Xie et al., 2010
AB1-Ntcp standard conditions Fig. 3 with image from Sakaguchi et al., 2008
Ab1-tjp1 chemical treatment by environment: miconazole Fig. 3 with image from Yang et al., 2017
Ab1-cldn5 standard conditions Fig. 3 from Yang et al., 2020
Fig. 2 with image,  Fig. 3 with image,  Fig. 6 with image from Xie et al., 2010
Ab6-cdh5 standard conditions Fig. 1 with image from Paatero et al., 2018
Ab5-tjp1a standard conditions Fig. 7, S2 with image from Fadeev et al., 2015
Ab9-mapk standard conditions Fig. 1 with image,  Fig. 5 with image from De Angelis et al., 2017
Fig. 4 from Krispin et al., 2017
Ab1-elnb standard conditions Fig. 1 with image from Bensimon-Brito et al., 2021
Ab-CS-56 standard conditions Fig. 3 with image from Peal et al., 2009
Ab3-prox1 standard conditions Fig. 1 with image,  Fig. 2 with image,  Fig. 3 with image,  Fig. 5 with image from Sakaguchi et al., 2008
Ab3-prox1 chemical treatment: semaxanib Fig. 4 with image from Sakaguchi et al., 2008
Ab1-esama standard conditions Fig. 1. with image,  Fig. 2. with image from Lee et al., 2021
Ab1-casp3 standard conditions Fig. 4 with image from Chetty et al., 2020
Ab1-cdh5 chemical treatment by environment: IWR-1-endo Fig. 4 from Hübner et al., 2018
Ab16-GFP standard conditions Fig. 4 with image from Chetty et al., 2020
Ab2-fn standard conditions Figure 3 with image from Duchemin et al., 2019
Fig. 10 with image from Mana et al., 2016
Fig. 3 with image from Chou et al., 2013
Ab1-tjp1 standard conditions Fig. 1. with image,  Fig. 2. with image,  Fig. 7. with image from Lee et al., 2021
Fig. 1 with image from Paatero et al., 2018
Fig. 3 with image from Yang et al., 2017
Fig. S3 with image from Yoruk et al., 2012
Fig. 3 from Li et al., 2010
Ab1-eng standard conditions Fig. 2 with image from Leigh et al., 2013
Ab1-BrdU chemical treatment: 5-bromo-2'-deoxyuridine Fig. 2 from Herzog et al., 2009
Ab7-mapk standard conditions Fig. 3 with image from Gong et al., 2019
Ab1-smad standard conditions Fig. 3 with image from Lenhart et al., 2013
Fig. 5 from Pi et al., 2012
zn-5 alcama standard conditions Fig. 4 from Shin et al., 2014
Fig. 3 with image from Schaub et al., 2012
Fig. 1 with image,  Fig. 2 with image,  Fig. 3 with image,  Fig. 5 with image from Sakaguchi et al., 2008
zn-8 standard conditions Fig. 3 with image from Donat et al., 2018
Fig. 5 with image from Lisowska et al., 2018
Fig. 2 with image,  Fig. 4 with image from Renz et al., 2015
Fig. 4 with image,  Fig. 6 with image from Patra et al., 2011
zn-5 chemical treatment: semaxanib Fig. 4 with image from Sakaguchi et al., 2008
Ab1-asip2b asip2b control Fig. 5 with image from Shainer et al., 2019
Ab1-cdh5 cdh5 standard conditions Fig. 2. with image,  Fig. 6. with image,  Fig. 7. with image,  Fig. 8. with image from Lee et al., 2021
Fig. 2 with image from Xu et al., 2017
Fig. 3 from Li et al., 2010
Fig. S9 from Kleaveland et al., 2009
Ab1-podxl2 podxl2 standard conditions Fig. 4 with image from Herwig et al., 2011
Ab1-rasip1 rasip1 standard conditions Fig. 6. with image,  Fig. 8. with image from Lee et al., 2021
Ab1-sema3d sema3d standard conditions Fig. 2 with image from Hamm et al., 2016
Ab1-tnfrsf21 tnfrsf21 control Fig. S3 with image from Tam et al., 2012
Ab2-tnfrsf21 control Fig. S3 with image from Tam et al., 2012
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions 222 figures with image from 126 publications
chemical treatment by environment: pharmaceutical 30 figures with image from 27 publications
amputation: caudal fin 21 figures with image from 13 publications
GFP standard conditions Fig. 1 with image from Khaliq et al., 2015
Fig. 2 with image,  Fig. 4 with image,  Fig. 6 with image from Renz et al., 2015
Fig. 3 from Weber et al., 2014
Fig. 3 with image,  Fig. S1 with image from Cameron et al., 2012
PHENOTYPE
Phenotype in s843Tg
Phenotype Conditions Figures
adrenal gland development process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image from Chou et al., 2014
adrenal gland development process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image from Chou et al., 2014
angiogenesis increased occurrence, abnormal chemical treatment by injection: trehalose 6,6'-dimycolate Fig. 2 with image,  Fig. 4,  Fig. S3 from Walton et al., 2018
angiogenesis increased occurrence, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 1 with image from Walton et al., 2018
angiogenesis increased occurrence, ameliorated chemical treatment by injection: trehalose 6,6'-dimycolate, chemical treatment by environment: pazopanib Fig. 4 from Walton et al., 2018
aortic arch diameter, normal chemical treatment: semaxanib Fig. 2 from Herzog et al., 2009
atrioventricular canal endocardium morphology, normal control Fig. 2 from Chen et al., 2013
atrioventricular canal endocardium cell normal amount, normal control Fig. 2 from Chen et al., 2013
atrioventricular valve development process quality, normal control Fig. 2 from Chen et al., 2013
blood glucose increased amount, abnormal chemical treatment by environment: D-glucose Fig. 1 from Carnovali et al., 2016
blood island atoh8 expression decreased distribution, abnormal chemical treatment: bone morphogenetic protein receptor antagonist Fig. 3 with image from Place et al., 2017
blood vasculature decreased branchiness, abnormal chemical treatment by environment: SB 203580 Fig. S2 with image from Zhang et al., 2017
blood vasculature decreased branchiness, abnormal chemical treatment by environment: sirolimus Fig. S2 with image from Zhang et al., 2017
blood vasculature decreased branchiness, abnormal chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester Fig. S2 with image from Zhang et al., 2017
blood vasculature EGFP expression decreased distribution, abnormal chemical treatment: SL-327 Fig. 7 with image from Chetty et al., 2020
blood vasculature morphology, abnormal chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester Fig. S2 with image from Zhang et al., 2017
blood vasculature morphology, abnormal chemical treatment by environment: sirolimus Fig. S2 with image from Zhang et al., 2017
blood vasculature morphology, abnormal chemical treatment by environment: SB 203580 Fig. S2 with image from Zhang et al., 2017
blood vasculature EGFP expression spatial pattern, abnormal chemical treatment: SL-327 Fig. 7 with image from Chetty et al., 2020
blood vessel endothelial cell normal amount, normal standard conditions Fig. 3 from Jin et al., 2017
blood vessel remodeling disrupted, abnormal chemical treatment: tricaine Fig. S13 with image from Chen et al., 2012
blood vessel remodeling disrupted, abnormal chemical treatment: diacetylmonoxime Fig. S13 with image from Chen et al., 2012
brain vasculature blood vessel endothelial cell ab1-cdh5 labeling decreased amount, abnormal chemical treatment by environment: IWR-1-endo Fig. 4 from Hübner et al., 2018
brain vasculature blood vessel endothelial cell ab1-cdh5 labeling increased amount, abnormal chemical treatment by environment: IWR-1-endo Fig. 4 from Hübner et al., 2018
brain vasculature vascular sprouts esama expression decreased amount, abnormal chemical treatment by environment: IWR-1-endo Fig. S4 from Hübner et al., 2018
caudal fin width, normal microgravity Fig. 2 from Xie et al., 2019
caudal vein absent, abnormal chemical treatment by injection: clodronic acid, chemical treatment by injection: carbon black nanoparticle, chemical treatment by injection: lipid micelle Fig. 5 with image from Campbell et al., 2018
caudal vein decreased length, abnormal chemical treatment by injection: clodronic acid, chemical treatment by injection: carbon black nanoparticle, chemical treatment by injection: lipid micelle Fig. 5 with image from Campbell et al., 2018
caudal vein length, normal chemical treatment by injection: clodronic acid Fig. 5 with image from Campbell et al., 2018
caudal vein morphology, normal chemical treatment by injection: clodronic acid Fig. 5 with image from Campbell et al., 2018
caudal vein plexus kdrl expression amount, ameliorated microgravity, chemical treatment: LY294002 Fig. 5 from Xie et al., 2019
caudal vein plexus kdrl expression decreased amount, abnormal chemical treatment: LY294002 Fig. 6 from Xie et al., 2019
caudal vein plexus decreased width, abnormal chemical treatment: LY294002 Fig. 6 from Xie et al., 2019
caudal vein plexus kdrl expression increased amount, abnormal microgravity Fig. 3 from Xie et al., 2019
caudal vein plexus increased width, abnormal microgravity Fig. 3 from Xie et al., 2019
caudal vein plexus malformed, abnormal chemical treatment by environment: nifedipine Fig. 1 from Xie et al., 2018
caudal vein plexus malformed, abnormal chemical treatment by environment: tricaine Fig. 1 from Xie et al., 2018
caudal vein plexus morphology, normal chemical treatment: DAPT Fig. 3 from Chappell et al., 2013
caudal vein plexus width, ameliorated microgravity, chemical treatment: LY294002 Fig. 5 from Xie et al., 2019
caudal vein plexus capillary amount, ameliorated microgravity, chemical treatment: LY294002 Fig. 5 from Xie et al., 2019
caudal vein plexus capillary area, ameliorated microgravity, chemical treatment: LY294002 Fig. 5 from Xie et al., 2019
caudal vein plexus capillary decreased amount, abnormal chemical treatment: LY294002 Fig. 6 from Xie et al., 2019
caudal vein plexus capillary decreased area, abnormal chemical treatment: LY294002 Fig. 6 from Xie et al., 2019
caudal vein plexus capillary increased amount, abnormal microgravity Fig. 3 from Xie et al., 2019
caudal vein plexus capillary increased area, abnormal microgravity Fig. 3 from Xie et al., 2019
caudal vein plexus sprouting angiogenesis decreased occurrence, abnormal chemical treatment by environment: tricaine Fig. 1 from Xie et al., 2018
caudal vein plexus sprouting angiogenesis decreased occurrence, abnormal chemical treatment by environment: nifedipine Fig. 1 from Xie et al., 2018
central artery decreased amount, abnormal chemical treatment: IWR-1-endo Fig. 3 with image from Vanhollebeke et al., 2015
central artery increased amount, abnormal chemical treatment: DAPT Fig. 2 with image from Bussmann et al., 2011
central artery vascular sprouts decreased amount, abnormal chemical treatment by environment: IWR-1-endo Fig. 1 from Hübner et al., 2018
cranial vasculature spatial pattern, normal standard conditions Fig. 6 with image from Liu et al., 2020
cranial vasculature structure, normal heat exposure Fig. 5 with image from Ton et al., 2018
dorsal aorta endothelial cell ab9-mapk labeling decreased amount, abnormal standard conditions Fig. 5 with image from De Angelis et al., 2017
dorsal aorta endothelial cell ab9-mapk labeling decreased distribution, abnormal standard conditions Fig. 5 with image from De Angelis et al., 2017
dorsal longitudinal anastomotic vessel malformed, abnormal chemical treatment: semaxanib Fig. 7 from Hassel et al., 2012
endothelial cell ccl38.1 expression amount, ameliorated control Fig. 3 from Page et al., 2019
endothelial cell mia expression amount, ameliorated control Fig. 3 from Page et al., 2019
endothelial cell tmem204 expression amount, ameliorated control Fig. 3 from Page et al., 2019
endothelial cell lft2 expression amount, ameliorated control Fig. 3 from Page et al., 2019
endothelial cell tmem204 expression amount, ameliorated chemical treatment: DAPT, chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell hlx1 expression amount, ameliorated control Fig. 3 from Page et al., 2019
endothelial cell tm4sf18 expression amount, ameliorated control Fig. 3 from Page et al., 2019
endothelial cell hmgcra expression amount, ameliorated control Fig. 3 from Page et al., 2019
endothelial cell mfng expression amount, ameliorated control Fig. 3 from Page et al., 2019
endothelial cell hlx1 expression decreased amount, abnormal chemical treatment: DAPT, chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell hlx1 expression decreased amount, abnormal chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell ccl38.1 expression decreased amount, abnormal chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell ccl38.1 expression decreased amount, abnormal chemical treatment: DAPT, chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell mia expression decreased amount, abnormal chemical treatment: DAPT, chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell mia expression decreased amount, abnormal chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell tmem204 expression decreased amount, abnormal chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell lft2 expression decreased amount, abnormal chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell lft2 expression decreased amount, abnormal chemical treatment: DAPT, chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell avpr1ab expression decreased amount, abnormal chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell avpr1ab expression decreased amount, abnormal chemical treatment: DAPT, chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell avpr1ab expression decreased amount, abnormal control Fig. 3 from Page et al., 2019
endothelial cell tm4sf18 expression decreased amount, abnormal chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell tm4sf18 expression decreased amount, abnormal chemical treatment: DAPT, chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell mfng expression decreased amount, abnormal chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell hmgcra expression decreased amount, abnormal chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell mfng expression decreased amount, abnormal chemical treatment: DAPT, chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell hmgcra expression decreased amount, abnormal chemical treatment: DAPT, chemical treatment: semaxanib Fig. 3 from Page et al., 2019
endothelial cell ccl38.1 expression increased amount, abnormal chemical treatment: DAPT Fig. 3 from Page et al., 2019
endothelial cell tm4sf18 expression increased amount, abnormal chemical treatment: DAPT Fig. 3 from Page et al., 2019
endothelial cell mfng expression increased amount, abnormal chemical treatment: DAPT Fig. 3 from Page et al., 2019
endothelial cell mia expression increased amount, abnormal chemical treatment: DAPT Fig. 3 from Page et al., 2019
endothelial cell hmgcra expression increased amount, abnormal chemical treatment: DAPT Fig. 3 from Page et al., 2019
endothelial cell tmem204 expression increased amount, abnormal chemical treatment: DAPT Fig. 3 from Page et al., 2019
endothelial cell avpr1ab expression increased amount, abnormal chemical treatment: DAPT Fig. 3 from Page et al., 2019
endothelial cell hlx1 expression increased amount, abnormal chemical treatment: DAPT Fig. 3 from Page et al., 2019
endothelial cell vegfaa expression increased amount, abnormal hypoxia Figure 7 with image from Ki et al., 2019
endothelial cell lft2 expression increased amount, abnormal chemical treatment: DAPT Fig. 3 from Page et al., 2019
female organism decreased life span, abnormal chemical treatment by environment: D-glucose Fig. 1 from Carnovali et al., 2016
granuloma formation decreased occurrence, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 3 with image from Torraca et al., 2017
heart morphology, normal standard conditions Fig. 4 from Chi et al., 2008
heart contraction decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image,  Fig. 3 with image from Chou et al., 2014
heart contraction decreased rate, abnormal microgravity Fig. 2 from Xie et al., 2019
heart contraction increased rate, abnormal chemical treatment: pharmaceutical Fig. 2 with image,  Fig. 3 with image from Chou et al., 2014
interrenal angiogenic sprout decreased length, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Chou et al., 2014
interrenal angiogenic sprout increased length, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Chou et al., 2014
interrenal gland animal organ morphogenesis process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image from Chou et al., 2014
interrenal gland animal organ morphogenesis process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image from Chou et al., 2014
intersegmental vessel decreased amount, abnormal chemical treatment: SL-327 Fig. 7 with image from Chetty et al., 2020
intersegmental vessel decreased amount, abnormal chemical treatment by environment: semaxanib Fig. 6 with image from De Angelis et al., 2017
intersegmental vessel EGFP expression decreased distribution, abnormal chemical treatment: SL-327 Fig. 7 with image from Chetty et al., 2020
intersegmental vessel has fewer parts of type cell, abnormal chemical treatment: semaxanib Fig. 7 from Hassel et al., 2012
intersegmental vessel increased branchiness, abnormal chemical treatment by environment: DAPT Fig. 7 with image from Zhou et al., 2015
intersegmental vessel increased branchiness, abnormal chemical treatment by environment: DAPT Fig. 7 from Wang et al., 2016
intersegmental vessel malformed, abnormal chemical treatment: semaxanib Fig. 7 from Hassel et al., 2012
intersegmental vessel morphology, abnormal chemical treatment by diet: sunitinib Fig. 4 from Kanada et al., 2014
intersegmental vessel morphology, abnormal chemical treatment: DAPT Fig. 3,  Fig. 5 from Chappell et al., 2013
intersegmental vessel normal amount, normal control Fig. 7 with image from Chetty et al., 2020
intersegmental vessel normal height, normal chemical treatment: SL-327 Fig. 7 with image from Chetty et al., 2020
intersegmental vessel normal height, normal control Fig. 7 with image from Chetty et al., 2020
intersegmental vessel EGFP expression spatial pattern, abnormal chemical treatment: SL-327 Fig. 7 with image from Chetty et al., 2020
intersegmental vessel spatial pattern, normal chemical treatment: SL-327 Fig. 7 with image from Chetty et al., 2020
intersegmental vessel spatial pattern, normal control Fig. 7 with image from Chetty et al., 2020
intersegmental vessel angiogenesis increased process quality, abnormal chemical treatment by environment: DAPT Fig. 7 with image from Zhou et al., 2015
intersegmental vessel angiogenesis process quality, abnormal chemical treatment: DAPT Fig. 3,  Fig. 5 from Chappell et al., 2013
intersegmental vessel angiogenic sprout amount, normal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
intersegmental vessel angiogenic sprout decreased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M, chemical treatment by environment: sunitinib Fig. 4 with image from Torraca et al., 2017
intersegmental vessel cell migration involved in sprouting angiogenesis arrested, abnormal chemical treatment: semaxanib Fig. 7 from Hassel et al., 2012
lateral dorsal aorta morphology, normal heat exposure Fig. 5 with image from Ton et al., 2018
liver morphology, normal standard conditions Fig. 5 with image from Sakaguchi et al., 2008
male organism decreased life span, abnormal chemical treatment by environment: D-glucose Fig. 1 from Carnovali et al., 2016
midbrain blood vasculature has fewer parts of type blood vessel, abnormal chemical treatment: diacetylmonoxime Fig. S13 with image from Chen et al., 2012
midbrain blood vasculature has fewer parts of type blood vessel, abnormal chemical treatment: tricaine Fig. S13 with image from Chen et al., 2012
midbrain blood vasculature morphology, abnormal chemical treatment: diacetylmonoxime Fig. S13 with image from Chen et al., 2012
midbrain blood vasculature morphology, abnormal chemical treatment: tricaine Fig. S13 with image from Chen et al., 2012
palatocerebral vein morphology, normal heat exposure Fig. 5 with image from Ton et al., 2018
pharyngeal vasculature decreased width, abnormal chemical treatment: vatalanib Fig. S9 with image from Fish et al., 2008
pharyngeal vasculature disorganized, abnormal chemical treatment: DAPT Fig. 3 from Porazzi et al., 2012
regenerating fin vasculature development decreased process quality, abnormal amputation: caudal fin, chemical treatment: IWR-1-endo Fig. 6 from Li et al., 2014
retina blood vessel broken, abnormal chemical treatment by environment: D-glucose Fig. 2 from Carnovali et al., 2016
retina blood vessel fragile, abnormal chemical treatment by environment: D-glucose Fig. 2 from Carnovali et al., 2016
retina blood vessel increased thickness, abnormal chemical treatment by environment: D-glucose Fig. 2 from Carnovali et al., 2016
retina blood vessel shape, abnormal chemical treatment by environment: D-glucose Fig. 2 from Carnovali et al., 2016
scale bglap expression decreased amount, abnormal chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
scale tnfsf11 expression decreased amount, abnormal chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
scale tnfrsf11b expression decreased amount, abnormal chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
scale decreased area, abnormal chemical treatment by environment: D-glucose Fig. 3 from Carnovali et al., 2016
scale morphology, abnormal chemical treatment by environment: D-glucose Fig. 3 from Carnovali et al., 2016
scale bone remodeling process quality, abnormal chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
scale bone resorption increased occurrence, abnormal chemical treatment by environment: D-glucose Fig. 3,  Fig. 4 from Carnovali et al., 2016
scale ossification involved in bone remodeling decreased occurrence, abnormal chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
sprouting angiogenesis increased occurrence, abnormal chemical treatment: DAPT Fig. 2 with image from Bussmann et al., 2011
subintestinal vein decreased length, abnormal chemical treatment: IWR-1-endo Fig. 5 from Li et al., 2014
subintestinal vein morphology, abnormal chemical treatment: IWR-1-endo Fig. 5 from Li et al., 2014
subintestinal venous plexus carcinoma present, abnormal cancer xenotransplantation Fig. 5 with image from Zhang et al., 2021
thyroid gland development decreased process quality, abnormal chemical treatment: DAPT Fig. 3 from Porazzi et al., 2012
thyroid primordium malformed, abnormal chemical treatment: DAPT Fig. 3 from Porazzi et al., 2012
trunk curved, abnormal chemical treatment: DAPT Fig. 5 from Ethell et al., 2014
trunk vasculature EGFP expression decreased amount, abnormal chemical treatment by environment: pharmaceutical Fig. 3 with image from Overman et al., 2017
trunk vasculature increased permeability, abnormal chemical treatment by environment: lipopolysaccharide Fig. 2 from Philip et al., 2017
trunk vasculature morphology, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 1 with image,  Fig. 2 with image,  Fig. 3 with image,  Fig. 4 with image from Torraca et al., 2017
trunk vasculature morphology, ameliorated bacterial treatment by injection: Mycobacterium marinum M, chemical treatment by environment: sunitinib Fig. 4 with image from Torraca et al., 2017
trunk vasculature response to bacterium process quality, abnormal bacterial treatment by injection: Mycobacterium marinum M, chemical treatment by environment: sunitinib Fig. 4 with image from Torraca et al., 2017
vasculature agenesis, abnormal chemical treatment by injection: methoxypoly(ethylene glycol), chemical treatment by injection: poly(caprolactone) polymer, chemical treatment by injection: curcumin Fig. 8 from Gou et al., 2011
vasculature agenesis, abnormal chemical treatment by injection: curcumin Fig. 8 from Gou et al., 2011
vasculature morphology, abnormal chemical treatment by injection: methoxypoly(ethylene glycol), chemical treatment by injection: poly(caprolactone) polymer, chemical treatment by injection: curcumin Fig. 8 from Gou et al., 2011
vasculature morphology, abnormal chemical treatment by injection: curcumin Fig. 8 from Gou et al., 2011
ventral wall of dorsal aorta cell population proliferation decreased process quality, abnormal chemical treatment: NS-398 Fig. 5 with image from Esain et al., 2015
ventral wall of dorsal aorta cell population proliferation increased process quality, abnormal chemical treatment: cannabinoid receptor agonist Fig. 5 with image from Esain et al., 2015
vertebral artery absent, abnormal chemical treatment by environment: sunitinib Fig. 3 with image from Matsuoka et al., 2017
vertebral artery absent, abnormal chemical treatment by environment: vascular endothelial growth factor receptor antagonist Fig. 3 with image from Matsuoka et al., 2017
vertebral artery absent, abnormal chemical treatment by environment: LY294002 Fig. 3 with image from Matsuoka et al., 2017
whole organism kdrl expression amount, ameliorated microgravity, chemical treatment: LY294002 Fig. 5 from Xie et al., 2019
whole organism fabp4a expression decreased amount, abnormal chemical treatment by environment: SB 203580 Fig. S2 with image from Zhang et al., 2017
whole organism EGFP expression decreased amount, abnormal chemical treatment by environment: pharmaceutical Fig. 3 with image from Overman et al., 2017
whole organism fabp4a expression decreased amount, abnormal chemical treatment by environment: sirolimus Fig. S2 with image from Zhang et al., 2017
whole organism fabp4a expression decreased amount, abnormal chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester Fig. S2 with image from Zhang et al., 2017
whole organism kdrl expression decreased amount, abnormal chemical treatment: LY294002 Fig. 6 from Xie et al., 2019
whole organism decreased size, abnormal chemical treatment: DAPT Fig. 5 from Ethell et al., 2014
whole organism cxcl11.1 expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism vegfaa expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism mmp9 expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism cxcl12a expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism tnfa expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism kdrl expression increased amount, abnormal microgravity Fig. 3 from Xie et al., 2019
whole organism cxcl18b expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism il1b expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism length, normal microgravity Fig. 2 from Xie et al., 2019
whole organism neoplasm decreased size, ameliorated chemical treatment by injection: gold nanoparticle, chemical treatment by injection: doxorubicin, cancer xenotransplantation Fig. 4 from Ahn et al., 2015
whole organism nitric oxide increased amount, abnormal microgravity Fig. 4 from Xie et al., 2019

CITATIONS  (297)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.